Conatus Pharmaceuticals Inc. (CNAT) Expected to Announce Quarterly Sales of $13.46 Million
Equities research analysts forecast that Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) will announce sales of $13.46 million for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for Conatus Pharmaceuticals’ earnings. The lowest sales estimate is $3.00 million and the highest is $19.25 million. The firm is expected to announce its next quarterly earnings results on Tuesday, November 14th.
On average, analysts expect that Conatus Pharmaceuticals will report full-year sales of $13.46 million for the current financial year, with estimates ranging from $16.00 million to $54.16 million. For the next financial year, analysts expect that the business will post sales of $36.26 million per share, with estimates ranging from $4.00 million to $72.04 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that follow Conatus Pharmaceuticals.
Conatus Pharmaceuticals (NASDAQ:CNAT) last posted its earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by $0.02. The business had revenue of $10 million during the quarter, compared to analysts’ expectations of $9.33 million. During the same period last year, the firm posted ($0.30) earnings per share.
Several research analysts recently issued reports on the company. Zacks Investment Research raised Conatus Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, July 24th. ValuEngine raised Conatus Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, May 24th. HC Wainwright reissued a “buy” rating and issued a $18.00 price objective on shares of Conatus Pharmaceuticals in a research report on Thursday, June 29th. Aegis reissued a “buy” rating and issued a $11.00 price objective on shares of Conatus Pharmaceuticals in a research report on Monday, May 15th. Finally, Stifel Nicolaus reissued a “buy” rating and issued a $10.00 price objective on shares of Conatus Pharmaceuticals in a research report on Thursday, August 3rd. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $13.39.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Acadian Asset Management LLC raised its position in Conatus Pharmaceuticals by 641.1% in the second quarter. Acadian Asset Management LLC now owns 1,097,945 shares of the biotechnology company’s stock valued at $6,324,000 after buying an additional 949,785 shares during the period. State Street Corp purchased a new stake in shares of Conatus Pharmaceuticals during the second quarter valued at approximately $2,092,000. Numeric Investors LLC purchased a new stake in shares of Conatus Pharmaceuticals during the second quarter valued at approximately $1,620,000. Northern Trust Corp increased its stake in shares of Conatus Pharmaceuticals by 640.6% in the second quarter. Northern Trust Corp now owns 297,152 shares of the biotechnology company’s stock valued at $1,712,000 after buying an additional 257,030 shares in the last quarter. Finally, Vanguard Group Inc. increased its stake in shares of Conatus Pharmaceuticals by 31.2% in the second quarter. Vanguard Group Inc. now owns 1,006,890 shares of the biotechnology company’s stock valued at $5,800,000 after buying an additional 239,373 shares in the last quarter. 22.96% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: “Conatus Pharmaceuticals Inc. (CNAT) Expected to Announce Quarterly Sales of $13.46 Million” was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this report can be accessed at https://www.americanbankingnews.com/2017/08/17/conatus-pharmaceuticals-inc-cnat-expected-to-announce-quarterly-sales-of-13-46-million.html.
Conatus Pharmaceuticals (CNAT) opened at 5.15 on Thursday. The firm’s market capitalization is $154.52 million. The firm has a 50-day moving average price of $5.86 and a 200-day moving average price of $5.63. Conatus Pharmaceuticals has a 1-year low of $1.45 and a 1-year high of $9.40.
About Conatus Pharmaceuticals
Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Conatus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.